Streetbeat News

SCYRF

Scryb Inc

https://www.relaymedical.com/

Industry

Surgical and Medical Instrument Manufacturing

Open

0.01

Mkt cap

4.8M

Volume

12K

High

0.01

P/E Ratio

-0.50

52-wk high

0.02

Low

0.01

Div yield

N/A

52-wk low

0.01

Scryb Inc. reported its Q1 2025 financial results, highlighting a 54% increase in total assets to $13.5 million, a $9.3 million gain from accounting changes for Cybeats Technologies, and a $1.36 million gain from selling its stake in the Fionet Rapid Response Group. The company also raised $1.1 million in a financing round and launched Raidian, an AI business.

Portfolio Pulse from

March 04, 2025 | 1:15 pm

Scryb Inc. has increased its investment in Cybeats Technologies Corp. by $500,000 through a private placement and additional open-market share purchases.

Portfolio Pulse from

February 24, 2025 | 12:15 pm

Scryb Inc. has secured over $1.1 million in convertible debenture financing, led by Plaza Capital. The debentures have a 12% annual interest rate and can be converted into common shares at $0.05 per share.

Portfolio Pulse from

February 03, 2025 | 12:15 pm

Scryb Inc. announced a non-brokered private placement of secured convertible debentures to raise up to $2 million. The debentures have a 12% annual interest rate and can be converted into common shares at $0.05 per share.

Portfolio Pulse from

January 06, 2025 | 2:15 am

Scryb Inc. has launched a new business unit called Raidian, which focuses on providing AI governance and compliance solutions for enterprises. This move aims to help businesses manage AI risks and streamline compliance in complex environments.

Portfolio Pulse from

December 08, 2024 | 5:15 pm

Scryb Inc. has completed a non-brokered private placement financing, raising $742,400 through the issuance of 29,696,000 units at $0.025 per unit. Each unit includes one common share and one common share purchase warrant.

Portfolio Pulse from

November 06, 2024 | 10:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.